Skip to content
Kwality Pharmaceuticals logo

Kwality Pharmaceuticals

KPL NSE
₹3,741.00 No trade today
P/E
47.89
View as Markdown
MCP
Close 4 Nov 2026 ₹3,741.00 +2,871.90 +330% 1Y
Start ₹869.10

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
24.10%
Debt to Equity
0.39
EPS (TTM)
₹78.11
Book Value
₹318.80
Market Cap
—
P/E (TTM)
47.89
P/B
11.73
ROE
22.60%
Dividend Yield
0.00%
EBITDA
₹121 Cr
52W High
₹3,949.00
52W Low
₹828.80
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Kwality Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Kwality Pharmaceuticals (this company)
₹3,741.0047.89₹3,728 Cr11.730.00%22.60%24.10%₹554 Cr₹81 Cr
Median 8 companies₹2,048.6043.35₹1,25,337 Cr7.290.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

62 Good

Data confidence 100/100

Category scores

Quality
68
Strong
Returns, margins, earnings quality 22% weight
Valuation
31
Poor
Cheap vs sector & own history 24% weight
Growth
97
Strong
Sales & profit trajectory 9% weight
Financial Health
64
Good
Solvency, leverage, coverage 9% weight
Momentum
96
Strong
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 34.8% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 18.1%
  • Company's median sales growth is 27.4% of last 10 years

Weaknesses

3
  • Stock is trading at 11.5 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 203 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsNeutral252
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
58.04
Neutral
MACD (12,26,9)
34.23
Bullish
SMA (50)
3,522.15
Bullish
SMA (200)
2,356.97
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+21.12%
5Y+13.93%
3Y+26.08%
1Y+35.95%
TTM+37.91%

Net profit

Net profit growth by window
10Y+52.27%
5Y+34.90%
3Y+52.21%
1Y+67.50%
TTM+88.37%

Operating cash flow

Operating cash flow growth by window
10YTurned positive
5Y−8.84%
3Y−25.43%
1Y−67.92%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+16.70 pp
5Y+12.39 pp
3Y−0.84 pp
1Y+1.84 pp
TTM+2.46 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹98.00 Cr
Mar 2018₹137 Cr
Mar 2019₹166 Cr
Mar 2020₹139 Cr
Mar 2021₹262 Cr
Mar 2022₹456 Cr
Mar 2023₹251 Cr
Mar 2024₹307 Cr
Mar 2025₹370 Cr
Mar 2026₹503 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹3.00 Cr
Mar 2018₹4.00 Cr
Mar 2019₹8.00 Cr
Mar 2020₹8.00 Cr
Mar 2021₹15.00 Cr
Mar 2022₹120 Cr
Mar 2023₹19.00 Cr
Mar 2024₹24.00 Cr
Mar 2025₹40.00 Cr
Mar 2026₹67.00 Cr

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Kwality Pharmaceuticals Ltd is a small-cap healthcare company with a market cap of ₹2,821 Cr, trading at a PE of 41.2x and 8.39x book value. The company has delivered strong profit growth of 35% CAGR over 5 years and ROE of 23% in the last year, but carries high debtor days of 203 and pays no dividend despite consistent profitability.

Bull Case 7
  • Strong profit growth with 35% CAGR over 5 years and TTM profit growth accelerating to 71%
  • Consistent ROE track record averaging 26% over 10 years, with 23% in the last year
  • Robust sales growth of 26% CAGR over 3 years and 36% TTM, indicating sustained demand
  • Median sales growth of 27.4% over last 10 years demonstrates long-term revenue consistency
  • Stock price CAGR of 100% over 3 years and 72% over 5 years reflects strong market re-rating
  • Company is expected to deliver a good upcoming quarter based on operational momentum
  • Long-term compounded profit growth of 44% over 10 years shows durable earnings power
Bear Case 7
  • High debtor days of 203 indicates significant working capital strain and potential collection risk
  • Price-to-book of 8.39x is elevated, suggesting the stock prices in substantial future growth
  • Zero dividend yield despite repeated profits suggests poor capital return to shareholders
  • Stock has surged 128% in 1 year, raising the risk of mean reversion or correction
  • Small market cap of ₹2,821 Cr implies lower liquidity and higher volatility risk
  • Debt-to-equity ratio is not disclosed, creating uncertainty around the balance sheet leverage
  • 52-week high and low data unavailable, limiting visibility into recent price range and support levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

Quarterly Results

₹ Cr
539997 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
67
70
78
92
80
90
84
116
111
111
123
157
162
Expenses
54
54
61
71
63
70
67
90
87
86
93
118
121
Operating Profit
14
15
17
21
17
20
18
26
24
25
30
39
41
OPM %
20%
22%
21%
22%
22%
22%
21%
22%
22%
23%
24%
25%
25%
Other Income
0
0
1
−7
0
0
1
1
0
1
0
1
1
Interest
2
2
3
3
2
3
2
2
3
3
2
3
3
Depreciation
5
5
5
5
4
5
5
5
5
5
5
5
5
PBT
7
8
10
6
11
13
11
19
17
18
22
32
34
Tax %
25%
24%
21%
29%
25%
33%
25%
24%
30%
23%
28%
20%
25%
Net Profit
5
6
8
4
8
8
9
14
12
14
16
25
26
EPS (₹)
5.22
6.01
7.41
4.2
8.06
8.16
8.22
13.96
11.5
13.61
15.43
24.38
24.69

Profit & Loss

₹ Cr
539997 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
52
74
98
137
166
139
262
456
251
307
370
503
554
Expenses
49
69
89
126
150
125
233
285
190
241
290
385
419
Operating Profit
3
5
9
12
16
14
29
172
61
66
80
118
135
OPM %
6%
7%
9%
8%
9%
10%
11%
38%
24%
22%
22%
24%
24%
Other Income
0
0
1
1
1
4
2
4
−14
−5
2
2
2
Interest
1
1
2
2
2
3
3
3
7
10
10
11
11
Depreciation
1
2
3
3
3
4
6
11
15
20
18
20
20
PBT
1
2
6
7
11
11
21
162
26
31
54
89
106
Tax %
41%
48%
42%
39%
31%
25%
30%
26%
25%
24%
26%
25%
—
Net Profit
1
1
3
4
8
8
15
120
19
24
40
67
81
EPS (₹)
0.92
1.55
3.23
4.39
7.28
8.02
14.6
116
18.67
22.94
38.41
64.91
78.11
Div. Payout %
0%
0%
9%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
539997 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
5
5
10
10
10
10
10
10
10
10
10
Reserves
15
17
20
19
27
36
51
171
190
214
254
321
Borrowings
8
13
19
26
29
35
41
54
90
98
112
130
Other Liabilities
10
17
26
40
39
52
64
105
70
72
71
130
Total Liabilities
37
51
71
96
105
133
166
341
361
394
447
592
Fixed Assets
13
13
17
20
29
43
57
92
120
139
146
156
CWIP
0
0
0
0
0
0
3
12
14
0
0
17
Investments
1
2
4
5
5
4
5
0
0
0
0
0
Other Assets
24
37
50
70
71
86
102
237
226
255
302
420
Total Assets
37
51
71
96
105
133
166
341
361
394
447
592

Cash Flow

₹ Cr
539997 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1
−3
4
−1
14
6
27
61
41
43
53
17
Investing
−1
−2
−7
−6
−12
−18
−23
−63
−48
−26
−29
−35
Financing
1
6
5
5
−2
12
1
6
1
−17
−14
7
Net Cash Flow
1
0
2
−1
0
0
4
3
−6
−1
10
−11
Free Cash Flow
0
−5
−2
−7
2
−12
3
5
−4
17
28
−29
CFO/OP
51
−30
76
21
108
62
115
59
78
67
85
32

Ratios

539997 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
63
89
84
98
84
79
50
55
104
136
152
203
Inventory Days
61
67
71
54
34
94
38
97
310
187
167
111
Days Payable
40
63
65
80
52
96
58
63
117
106
112
144
Cash Conversion Cycle
85
93
90
73
67
77
30
90
297
217
208
170
Working Capital Days
35
41
20
18
20
43
24
60
118
101
98
128
ROCE %
9%
13%
19%
19%
22%
18%
26%
98%
19%
16%
18%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kwality Pharmaceuticals insights

65 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 54.86%
  • Public 31.26%
  • Others 10.31%
  • FIIs 2.50%
  • DIIs 1.07%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Documents

Frequently Asked Questions about Kwality Pharmaceuticals

What does Kwality Pharmaceuticals Ltd do?
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products
Where is Kwality Pharmaceuticals Ltd (KPL) listed?
Kwality Pharmaceuticals Ltd trades as KPL on the NSE and under code 539997 on the BSE.
Which sector does Kwality Pharmaceuticals Ltd belong to?
Kwality Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd trades at a PE ratio of 47.89 as of 4 Nov 2026, on earnings per share of ₹78.11, against a book value of ₹318.8 per share.
What is the 52-week high and low of Kwality Pharmaceuticals Ltd?
Over the last 52 weeks Kwality Pharmaceuticals Ltd has traded between ₹828.8 and ₹3,949 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd reported a return on equity of 22.60%. Its debt-to-equity ratio is 0.39.

Company Information

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products

Website kwalitypharma.com
Listed 18 Jul 2016
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539997.md for Kwality Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month